Latest Commercialisation Strategy News

Hazer Group Limited has opened a $2 million underwritten Share Purchase Plan, offering eligible shareholders in Australia and New Zealand the chance to buy shares at the same price as a recent institutional placement. The funds will support the commercialisation of its methane reactor technology and synthetic graphite development.

Clarity Pharmaceuticals has partnered with SpectronRx to manufacture and distribute its lead prostate cancer diagnostic, Cu-64 SAR-bisPSMA, at commercial scale across the US. This agreement sets the stage for a seamless launch pending FDA approval.

HeraMED has partnered with RMIT University and the Digital Health CRC to develop AI-driven maternity care models focused on culturally diverse populations, aiming to improve pre-term delivery risk prediction and personalised care.

Hazer Group has raised A$8 million through a share placement and launched a A$2 million Share Purchase Plan to accelerate its clean hydrogen and graphite technology commercialisation.

FBR Limited has secured a pivotal engineering agreement with Samsung Heavy Industries to develop a shipbuilding automation robot, marking a significant step in industrial robotics innovation.

Omega Oil and Gas has extinguished a 3% royalty on its Queensland liquids production by paying TAG Oil US$1 million, clearing the way for greater commercial flexibility following promising flow tests at Canyon-1H.

Tivan Limited has received $150,000 in exploration grants from the Northern Territory Government to advance its promising Sandover Fluorite Project, supporting maiden drilling and metallurgical testwork.

Papyrus Australia has secured a pivotal contract with UniSA to establish a Rapid Prototyping and R&D facility, advancing its sustainable packaging technology and commercial production plans.

Nanollose Limited has appointed Andrew Moullin as its new CEO and Managing Director, aiming to leverage his extensive commercial expertise to fast-track the company’s microbial cellulose technology towards market readiness.

Avecho Biotechnology has received $1.66 million from the Australian Government’s R&D Tax Incentive, reinforcing its commitment to a pivotal Phase III trial for its CBD-based insomnia treatment and accelerating its commercial ambitions.

EBR Systems has announced a fully underwritten A$55.9 million capital raise alongside a Security Purchase Plan to fund the commercial rollout of its FDA-approved WiSE CRT System, targeting a US$3.6 billion market opportunity in cardiac resynchronization therapy.

EBR Systems has raised A$55.9 million through a fully underwritten placement to fund the commercial rollout of its FDA-approved wireless cardiac pacing system, with plans for a limited market release in H2 2025 and expanded distribution in 2026.